Hepalink reports mixed Q3 2025 as profit falls despite revenue growth

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. released its 2025 third quarterly report, showing total operating revenue for the nine months ended September 30, 2025, increased by 3.09% year-on-year to RMB4,194,464,397.94. However, net profit attributable to the shareholders of the listed company decreased by 29.04% to RMB553,575,740.56, with basic and diluted earnings per share also falling by 29.04% to RMB0.3773.

The company's total assets saw a slight decline of 1.24% to RMB17,127,883,896.47 as of September 30, 2025, compared to the end of last year. Owners' equity attributable to shareholders, however, increased by 1.82% to RMB12,369,636,451.02. Net cash flows from operating activities for the period decreased by 19.60% to RMB1,440,949,279.15.

Key balance sheet changes include a 46.69% increase in financial assets held for trading, mainly due to increased purchases of wealth management products. Construction in progress decreased by 78.62% as a Pingshan formulation line was converted to fixed assets. Long-term borrowings decreased by 59.69%, primarily due to repayments and reclassification to non-current liabilities due within one year.